Leukemia
-
Publication Venue For
- Treatment outcomes of triple class refractory multiple myeloma: a benchmark for new therapies.. 36:877-880. 2022
- Validation and refinement of a RUNX1 mutation-associated gene expression signature in blast crisis chronic myeloid leukemia.. 36:892-896. 2022
- Polygenic risk score and risk of monoclonal B-cell lymphocytosis in caucasians and risk of chronic lymphocytic leukemia (CLL) in African Americans.. 36:119-125. 2022
- Outcomes of patients with IDH1-mutant relapsed or refractory acute myeloid leukemia receiving ivosidenib who proceeded to hematopoietic stem cell transplant.. 35:3278-3281. 2021
- Adverse event burden in older patients with CLL receiving bendamustine plus rituximab or ibrutinib regimens: Alliance A041202.. 35:2854-2861. 2021
- Association between high-density lipoprotein cholesterol level and risk of hematologic malignancy.. 35:1356-1364. 2021
- A dose-finding Phase 2 study of single agent isatuximab (anti-CD38 mAb) in relapsed/refractory multiple myeloma.. 34:3298-3309. 2020
- Good prognosis or poor prognosis, dose-intensive or less intensive: who decides for adults with T-lymphoblastic lymphoma/leukemia.. 34:3075-3076. 2020
- Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials.. 34:2430-2440. 2020
- Hematopoietic stem cell transplantation for adults with T-cell lymphoblastic lymphoma: can we successfully step into the era of precision medicine?. 34:1213-1214. 2020
- Randomized assessment of delayed intensification and two methods for parenteral methotrexate delivery in childhood B-ALL: Children's Oncology Group Studies P9904 and P9905.. 34:1006-1016. 2020
- A prospective evaluation of pegylated interferon alfa-2a therapy in patients with polycythemia vera and essential thrombocythemia with a prior splanchnic vein thrombosis.. 33:2974-2978. 2019
- Allogeneic hematopoietic cell transplantation compared to chemotherapy consolidation in older acute myeloid leukemia (AML) patients 60-75 years in first complete remission (CR1): an alliance (A151509), SWOG, ECOG-ACRIN, and CIBMTR study.. 33:2599-2609. 2019
- Heritable variation at the chromosome 21 gene ERG is associated with acute lymphoblastic leukemia risk in children with and without Down syndrome.. 33:2746-2751. 2019
- Quality of life and mood of older patients with acute myeloid leukemia (AML) receiving intensive and non-intensive chemotherapy.. 33:2393-2402. 2019
- Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy.. 33:2266-2275. 2019
- Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia.. 33:1835-1850. 2019
- Recurrent PDGFRB mutations in unicentric Castleman disease.. 33:1035-1038. 2019
- Relative survival following response to 7 + 3 versus azacytidine is similar in acute myeloid leukemia and high-risk myelodysplastic syndromes: an analysis of four SWOG studies.. 33:371-378. 2019
- Second cycle remission achievement with 7+3 and survival in adults with newly diagnosed acute myeloid leukemia: analysis of recent SWOG trials.. 33:554-558. 2019
- Phase 1/2 trial of GCLAM with dose-escalated mitoxantrone for newly diagnosed AML or other high-grade myeloid neoplasms.. 32:2352-2362. 2018
- Early relapse after autologous hematopoietic cell transplantation remains a poor prognostic factor in multiple myeloma but outcomes have improved over time.. 32:986-995. 2018
- Targeting nucleolin for better survival in diffuse large B-cell lymphoma.. 32:663-674. 2018
- PD-L1 is commonly expressed and transcriptionally regulated by STAT3 and MYC in ALK-negative anaplastic large-cell lymphoma.. 31:1633-1637. 2017
- Loss of PRDM1/BLIMP-1 function contributes to poor prognosis of activated B-cell-like diffuse large B-cell lymphoma.. 31:625-636. 2017
- Citrullination of histone H3 drives IL-6 production by bone marrow mesenchymal stem cells in MGUS and multiple myeloma.. 31:373-381. 2017
- Effect of measurable ('minimal') residual disease (MRD) information on prediction of relapse and survival in adult acute myeloid leukemia.. 30:2080-2083. 2016
- Loss of the mismatched human leukocyte antigen haplotype in two acute myelogenous leukemia relapses after haploidentical bone marrow transplantation with post-transplantation cyclophosphamide.. 30:2102-2106. 2016
- Prediction of CR following a second course of '7+3' in patients with newly diagnosed acute myeloid leukemia not in CR after a first course.. 30:1779-1780. 2016
- JAK-STAT and G-protein-coupled receptor signaling pathways are frequently altered in epitheliotropic intestinal T-cell lymphoma.. 30:1311-1319. 2016
- A functional polymorphism in the CEBPE gene promoter influences acute lymphoblastic leukemia risk through interaction with the hematopoietic transcription factor Ikaros.. 30:1194-1197. 2016
- Prognostic and biologic significance of DNMT3B expression in older patients with cytogenetically normal primary acute myeloid leukemia.. 29:567-575. 2015
- Effect of FTY720 on the SET-PP2A complex in acute myeloid leukemia; SET binding drugs have antagonistic activity.. 28:1915-1918. 2014
- Declining rates of treatment-related mortality in patients with newly diagnosed AML given 'intense' induction regimens: a report from SWOG and MD Anderson.. 28:289-292. 2014
- Application of the international prognostic scoring system-revised in therapy-related myelodysplastic syndromes and oligoblastic acute myeloid leukemia.. 28:185-189. 2014
- Associations between genome-wide Native American ancestry, known risk alleles and B-cell ALL risk in Hispanic children.. 27:2416-2419. 2013
- Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial.. 27:1902-1909. 2013
- Chronic lymphocytic leukemia and regulatory B cells share IL-10 competence and immunosuppressive function.. 27:170-182. 2013
- Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study.. 26:2103-2113. 2012
- The vascular niche: home for normal and malignant hematopoietic stem cells.. 26:54-62. 2012
- Immunophenotypic and gene expression analysis of monoclonal B-cell lymphocytosis shows biologic characteristics associated with good prognosis CLL.. 25:1459-1466. 2011
- Escalation of daunorubicin and addition of etoposide in the ADE regimen in acute myeloid leukemia patients aged 60 years and older: Cancer and Leukemia Group B Study 9720.. 25:800-807. 2011
- LMP-420: a novel purine nucleoside analog with potent cytotoxic effects for CLL cells and minimal toxicity for normal hematopoietic cells.. 24:1580-1587. 2010
- Bortezomib, dexamethasone, cyclophosphamide and lenalidomide combination for newly diagnosed multiple myeloma: phase 1 results from the multicenter EVOLUTION study.. 24:1350-1356. 2010
- Long-term results of Dana-Farber Cancer Institute ALL Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1985-2000).. 24:320-334. 2010
- Single-cell analysis reveals oligoclonality among 'low-count' monoclonal B-cell lymphocytosis.. 24:133-140. 2010
- Apolipoprotein E genotype as a determinant of survival in chronic lymphocytic leukemia.. 22:2184-2192. 2008
- Sequential myeloablative autologous stem cell transplantation and reduced intensity allogeneic hematopoietic cell transplantation is safe and feasible in children, adolescents and young adults with poor-risk refractory or recurrent Hodgkin and non-Hodgkin lymphoma. 2015